2025 How effective is the prescription drug giritinib fumarate tablets in the treatment of FLT3 mutated leukemia? Price reference at home and abroad is here!

Acute myeloid leukemia (AML) is a highly heterogeneous malignant hematological disease. About one-third of patients have FLT3 gene mutations, especially FLT3-ITD (internal tandem duplication). This mutation is closely associated with rapid disease progression, high recurrence rate, and poor prognosis. As the first oral targeted drug approved for FLT3-mutated R/R AML, the emergence of Gilteritinib has rewritten the treatment landscape of this high-risk subtype.

Different from traditional chemotherapy, giritinib, as a multi-target tyrosine kinase inhibitor (TKI), can selectively inhibit the signaling pathways related to FLT3-ITD and FLT3-TKD mutations, inhibit the proliferation of leukemia cells, and promote their apoptosis. The latest research shows that it also has a certain inhibitory effect on leukemia clones carrying multiple FLT3 subtype mutations (such as FLT3-ITD + D835), laying the foundation for anti-drug resistance strategies.

xa0

1. GiritinibNew breakthrough in FL3T targeting mechanism: unlocking the direction of AML treatment

Giritinib is one of the most representative targeted drugs currently used in the treatment of relapsed or refractory acute myeloid leukemia (AML). It has shown efficacy especially in AML patients with FLT3 mutations. Unlike traditional chemotherapy, giritinib inhibits the signaling pathways and proliferation of tumor cells by highly selectively targeting FMS-like tyrosine kinase 3 (FLT3) mutations, thereby inducing cell apoptosis and improving prognosis.

The latest research shows that giritinib is not only effective against commonFLT3-ITD mutations, but can also target drug-resistant subtypes such as FLT3-TKD (such as D835). This multi-target mechanism makes it a powerful candidate for both monotherapy and combination therapy, especially in patients who have previously failed to respond to standard induction or consolidation chemotherapy.

2. Relapse/Refractory AML: GiritinibInterpretation of the latest indications

According to the latest guidelines, giritinib is suitable for adult patients with relapsed or refractory AML who are confirmed to be positive forFLT3 mutations. The discovery of FLT3 mutations requires molecular detection tools, such as PCR or NGS technology, to ensure that the patient's genotype matches the targeted drug, thereby improving the effect of personalized treatment.

In addition toR/R AML, multiple clinical trials are also exploring the potential role of geritinib in treatment-naïve AML, minimal residual disease (MRD)-positive status, and post-transplantation maintenance therapy. A 2025 study pointed out that giritinib used for consolidation therapy may delay disease progression and improve disease-free survival (DFS), providing more possibilities for AML treatment strategies.

xa0

3. Recommended dosage and medication management strategy of giritinib: drug resistance monitoring is particularly critical

The recommended initial dose of giritinib is 120mg orally administered daily which may be taken with food. Based on pharmacokinetic studies, its half-life is approximately 113 hours, allowing once-daily dosing. Clinical observation shows that most patients gradually develop efficacy within the first 1 to 2 months, so treatment should be maintained for at least 6 months to evaluate the true response.

Hematological indicators, electrocardiogram and creatine kinase levels should be closely monitored in the early stage of treatment to avoid potential QT prolongation or rhabdomyolysis and other rare adverse events. After disease response is observed, dose maintenance or, under certain circumstances, tapering may be considered.

For patients with mild to moderate hepatic and renal impairment, current studies have not shown the need for dose adjustment, but patients with severe hepatic and renal impairment still need to be carefully evaluated.

4. Clinical efficacy of giritinib:ADMIRAL study results

According tolong-term follow-up data from the ADMIRAL study, giritinib improves the overall survival (OS) and complete remission rate (CR) of patients with FLT3-mutated AML. In a head-to-head comparison compared with standard chemotherapy, the median OS in the gilitinib group reached 9.3 months, compared with 5.6 months in the chemotherapy group, and the CR rate increased to 21.1%.

In addition, this study shows that giritinib can cause a decrease in peripheral blood leukocyte count and clearance of bone marrow blasts in the first cycle of treatment, effectively controlling leukemia burden and delaying relapse time. In a real-world study, patients who were treated with giritinib bridging therapy before transplantation also had significantly better overall survival and recurrence-free survival (RFS) than those who did not.

xa0

5. Global Price Comparison of Original and Generic Drugs of Giritinib: Suggestions on Cost Control Strategies

1.Original drug price overview (trade name: Xospata)

The original product of giritinib fumarate tablets is developed and produced by Japan's Astellas Pharma (Astellas Pharma), with the trade name Xospata. According to drug price platform data:

1) European market: 40mg×84 tablets is about RMB 210,000;

2) Hong Kong and Macau market: Because there is no medical insurance coverage, the price is higher than , and each box can reach about RMB90,000 RMB.

3)Domestic market conditions

Giritinib has been approved for marketing in mainland China, but it has not yet been included in the national medical insurance catalog. The common specifications are40mg 42 tablets and 2 boards. The price of a single box is around 25,000 yuan, which brings a considerable financial burden to most families.

2.Generic drug price reference: taking the Laos version as an example

The price of the generic version of giritinib (specification: 40mg*90 tablets) launched by Lucius Pharmaceuticals in Laos is as low as about 2,000 yuan. It contains the same API ingredients and there is no significant difference in efficacy. However, clinical use should be carried out under the guidance of a physician to ensure that the source is regular and the batch number is legal.

xa0

3.Combining policies and medical insurance trends: When will geritinib be “affordable”

With the advancement of China's "Major New Drug Creation Project", geritinib is expected to be included in the "candidate list" of medical insurance negotiations in 2025. If price negotiations are successfully completed, patients' out-of-pocket payments are expected to drop significantly.

6. Precautions for the use of giritinib and response to resistance: mutation monitoring is key

During the use of giritinib, adverse events such as bone marrow suppression, muscle enzyme elevation, and QT interval prolongation should be prevented. Regular electrocardiograms and creatine kinase monitoring can help identify signs of toxicity early.

For the acquired drug resistance in some patients, studies have found that secondary mutations such asFLT3-F691L are the main reasons. To address this challenge, researchers are developing second-generation FLT3 inhibitors (such as FF-10101, MRX-2843) or guiding treatment switching through more precise NGS target monitoring.

xa0

7. Real feedback from treatment practice: How do patients evaluate the value of giritinib?

Overall, its effect on FLT3 mutation patients is obvious, and it is especially suitable for second-line selection after recurrence or bridging before transplantation. However, some patients develop QT interval prolongation or mild hepatotoxicity during the 3-4 weeks of medication, and need to suspend or adjust the dose. In summary, giritinib is more suitable for high-risk patients who need rapid disease control but are intolerant to highly toxic chemotherapy.

Summary: Giritinib isa new paradigm for AML targeted therapy, but “expensive” is still the threshold

Giritinib fumarate tablets are an innovative drug that targetsFLT3 mutations, and its efficacy in R/R AML patients has been verified by a large number of international studies. Whether it is the response rate of a single drug or as a bridging treatment for hematopoietic stem cell transplantation, its clinical value cannot be ignored. But the current high price is still a key obstacle limiting its widespread use.

xa0

Overseas reference links:

https://www.fda.gov/drugs/drug-approvals/gilteritinib-xospata

https://www.ema.europa.eu/en/medicines/human/EPAR/xospata

https://clinicaltrials.gov/ct2/results?cond=AML&term=gilteritinib

https://ashpublications.org/blood/article/144/Supplement%201/220/497618

https://pubmed.ncbi.nlm.nih.gov/36812345/

xa0